Compare ACET & PDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | PDC |
|---|---|---|
| Founded | 1947 | 2018 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 24.2M |
| IPO Year | 2017 | 2022 |
| Metric | ACET | PDC |
|---|---|---|
| Price | $2.48 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | ★ 284.0K | 72.2K |
| Earning Date | 11-05-2026 | 09-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.13 |
| 52 Week High | $9.97 | $8.40 |
| Indicator | ACET | PDC |
|---|---|---|
| Relative Strength Index (RSI) | 15.77 | 31.10 |
| Support Level | N/A | N/A |
| Resistance Level | $9.51 | $3.23 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 6.57 | 7.06 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.